Calidi Biotherapeutics Net Worth

Calidi Biotherapeutics Net Worth Breakdown

  CLDI
The net worth of Calidi Biotherapeutics is the difference between its total assets and liabilities. Calidi Biotherapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Calidi Biotherapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Calidi Biotherapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Calidi Biotherapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Calidi Biotherapeutics stock.

Calidi Biotherapeutics Net Worth Analysis

Calidi Biotherapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Calidi Biotherapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Calidi Biotherapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Calidi Biotherapeutics' net worth analysis. One common approach is to calculate Calidi Biotherapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Calidi Biotherapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Calidi Biotherapeutics' net worth. This approach calculates the present value of Calidi Biotherapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Calidi Biotherapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Calidi Biotherapeutics' net worth. This involves comparing Calidi Biotherapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Calidi Biotherapeutics' net worth relative to its peers.
To determine if Calidi Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Calidi Biotherapeutics' net worth research are outlined below:
Calidi Biotherapeutics generated a negative expected return over the last 90 days
Calidi Biotherapeutics has high historical volatility and very poor performance
Calidi Biotherapeutics may become a speculative penny stock
Calidi Biotherapeutics has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K.
Calidi Biotherapeutics generates negative cash flow from operations
About 20.0% of the company shares are held by company insiders
Calidi Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Calidi Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Calidi Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Follow Calidi Biotherapeutics' market capitalization trends

The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.13 M.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Calidi Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Calidi Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Calidi Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Leftwich Scott over a week ago
Acquisition by Leftwich Scott of 11684 shares of Calidi Biotherapeutics subject to Rule 16b-3
 
Andrew Jackson over a month ago
Acquisition by Andrew Jackson of 30000 shares of Calidi Biotherapeutics at 1.58 subject to Rule 16b-3
 
Stewart Alan R. over two months ago
Acquisition by Stewart Alan R. of 20217 shares of Calidi Biotherapeutics at 1.09 subject to Rule 16b-3
 
Stewart Alan R. over three months ago
Acquisition by Stewart Alan R. of 25995 shares of Calidi Biotherapeutics subject to Rule 16b-3
 
Leftwich Scott over six months ago
Acquisition by Leftwich Scott of 11684 shares of Calidi Biotherapeutics subject to Rule 16b-3
 
Allan Camaisa over six months ago
Disposition of 10000 shares by Allan Camaisa of Calidi Biotherapeutics at 1.62 subject to Rule 16b-3
 
Allan Camaisa over a year ago
Acquisition by Allan Camaisa of 70155 shares of Calidi Biotherapeutics at 1.15 subject to Rule 16b-3
 
Peoples George over a year ago
Insider Trading
 
Andrew Jackson over a year ago
Acquisition by Andrew Jackson of 300000 shares of Calidi Biotherapeutics at 0.195 subject to Rule 16b-3
 
Schoeneck James A over a year ago
Disposition of 375000 shares by Schoeneck James A of Calidi Biotherapeutics at 0.2 subject to Rule 16b-3
 
Schoeneck James A over a year ago
Acquisition by Schoeneck James A of 375000 shares of Calidi Biotherapeutics at 0.6 subject to Rule 16b-3
 
Allan Camaisa over a year ago
Acquisition by Allan Camaisa of 100000 shares of Calidi Biotherapeutics subject to Rule 16b-3
Calidi Biotherapeutics time-series forecasting models is one of many Calidi Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Calidi Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Calidi Biotherapeutics Earnings per Share Projection vs Actual

Calidi Biotherapeutics Corporate Management

Andrew JacksonChief OfficerProfile
PharmD SantidrianHead OfficerProfile
Stephen ThesingChief OfficerProfile
Thomas HerrmannManaging DevelopmentProfile
Wendy EsqChief OfficerProfile
When determining whether Calidi Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Calidi Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Calidi Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Calidi Biotherapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calidi Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks.
For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calidi Biotherapeutics. If investors know Calidi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Calidi Biotherapeutics is measured differently than its book value, which is the value of Calidi that is recorded on the company's balance sheet. Investors also form their own opinion of Calidi Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calidi Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calidi Biotherapeutics' market value can be influenced by many factors that don't directly affect Calidi Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calidi Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calidi Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calidi Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.